NCT05171790

A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

A Multicenter, Open Phase 1b Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Advanced Malignant Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 419 (actual)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This a multi-center, open-label, non-randomized phaseⅠb trail. The purpose of this study was to evaluate the efficacy and safety of QL1706 in patients with advanced solid tumors and to investigate the immunogenicity and pharmacokinetic characteristics of QL1706.

Detailed description

The study was divided into screening/baseline, treatment and follow-up periods. Efficacy assessment and safety monitoring will be conducted throughout the study period. Subjects will continue study treatment until disease progression occurs (unless the investigator believes there is a sustained clinical benefit) or other criteria for discontinuing study treatment are met, whichever occurs first.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	QL1706 injection	5 mg/kg, IV, Q3w

Timeline

• Start date: 2021-01-11
• Primary completion: 2021-12-31
• Completion: 2023-12-01
• First posted: 2021-12-29
• Last updated: 2023-04-07

Locations

1 site across 1 country: China